SNN - Smith & Nephew plc

NYSE - NYSE Delayed price. Currency in USD
35.47
+0.36 (+1.03%)
As of 4:02PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close35.11
Open35.38
Bid35.39 x 100
Ask35.42 x 700
Day's range0.00 - 0.00
52-week range
Volume161
Avg. volume644,152
Market cap15.551B
Beta0.25
PE ratio (TTM)20.22
EPS (TTM)1.75
Earnings dateN/A
Forward dividend & yield0.70 (1.95%)
Ex-dividend date2018-04-05
1y target est41.43
Trade prices are not sourced from all markets
  • PR Newswire20 days ago

    UK’s NICE Publishes a Medtech Innovation Briefing on PICO™ for the Prophylactic Use in Surgically Closed Incisions to Reduce Surgical Site Complications

    LONDON and NEW YORK , July 3, 2018 /PRNewswire/ -- Smith & Nephew (LSE: SN) (NYSE: SNN), the global medical technology business, announces that the UK's National Institute for Health and Care Excellence ...

  • Is Smith & Nephew plc’s (LON:SN.) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.2 months ago

    Is Smith & Nephew plc’s (LON:SN.) Balance Sheet Strong Enough To Weather A Storm?

    The size of Smith & Nephew plc (LSE:SN.), a UK£11.91B large-cap, often attracts investors seeking a reliable investment in the stock market. Big corporations are much sought after by risk-averseRead More...

  • Reuters - UK Focus3 months ago

    Smith & Nephew, financials knock FTSE off 3-month high

    Britain's top share index slipped on Thursday as a tumble in Smith & Nephew's shares and weakness across financials and health stocks dragged the FTSE 100 off a three-month high. Despite a firmer start to trading and a weaker pound, the blue chip FTSE 100 turned lower and ended the session down 0.54 percent at 7,502.69 points, only slightly outperforming a negative European market.

  • Why the flu season has helped leave Smith & Nephew feeling cold
    Sky News3 months ago

    Why the flu season has helped leave Smith & Nephew feeling cold

    With (Other OTC: WWTH - news) the population ageing in most rich countries round the world, these should in theory be bumper times for Smith & Nephew (Frankfurt: 502816 - news) , Europe's largest maker of artificial knees, shoulders and hips. It's a disappointing last trading update for Olivier Bohuon, who steps down as chief executive on Monday, although in his defence, the Frenchman - a pharmacy graduate - can point out that he has doubled the share price since he took the job in 2011. One is that Smith & Nephew is seeing weakness in a product area for which it is slightly less well-known - advanced wound management, which supplies ointments, bandages and dressings to healthcare suppliers.

  • MarketWatch3 months ago

    FTSE 100 breaks 5-day win streak as investors weigh Fed’s next move

    U.K. stocks dropped Thursday, following a five-session winning streak for the blue-chip market, with the focus on the U.S. Federal Reserve decision and its flagging of stronger inflation. Stocks were little changed after a reading on British services activity missed expectations. Shares of Smith & Nephew posted the biggest loss in London after a revenue warning.

  • Reuters - UK Focus3 months ago

    LIVE MARKETS-FTSE out of the red as weak data hits pound again

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus3 months ago

    Commodities help Britain's FTSE outperform while Smith & Nephew tumbles

    A strong outlook from miner Glencore and gains in oil stocks provided the bedrock for British shares to outperform stock markets on the continent on Thursday. Mining and energy stocks helped the FTSE stay ...

  • Reuters3 months ago

    Outgoing Smith & Nephew CEO signs off with a downgrade

    Smith & Nephew downgraded its revenue and profit forecasts after a weak first quarter on Thursday, days before Chief Executive Olivier Bohuon will end his seven-year tenure at the artificial knee and hip maker. It also lowered trading profit forecasts, predicting a margin at or above the level achieved last year rather than the 30-70 basis point growth it had targeted. Bohuon, who steps down on Monday, said the business had seen a "mixed performance" in the quarter to end-March, with established markets like the United States and Europe down 2 percent on an underlying basis and emerging markets up 9 percent, resulting in a flat result overall.

  • Reuters - UK Focus3 months ago

    Outgoing Smith & Nephew CEO signs off with a downgrade

    Smith & Nephew (Frankfurt: 502816 - news) downgraded its revenue and profit forecasts after a weak first quarter on Thursday, days before Chief Executive Olivier Bohuon will end his seven-year tenure at the artificial knee and hip maker. It also lowered trading profit forecasts, predicting a margin at or above the level achieved last year rather than the 30-70 basis point growth it had targeted.

  • Reuters - UK Focus3 months ago

    European shares dip on heavy earnings day as euro rebounds

    European bourses fell in morning trading on Thursday, weighed down by a rebound in the euro and a series of disappointing earning updates including from Smith & Nephew. The pan-European STOXX 600 index ...

  • Reuters - UK Focus3 months ago

    BUZZ-Smith & Nephew: guidance cut spurs worst day in 9 years

    ** Europe's biggest artificial hip and knee maker slumps 6.1 pct, biggest one-day drop since March 2009 ** Co cuts forecast for 2018 underlying revenue growth and profit margin after some markets softened ...

  • Reuters - UK Focus3 months ago

    Smith & Nephew downgrades outlook after weak Q1

    Smith & Nephew, Europe's biggest artificial hip and knee maker, downgraded its forecast for full-year underlying revenue growth and profit margin after some markets softened and it saw a slowdown in its ...

  • Reuters4 months ago

    Smith & Nephew picks new CEO who sold his last company

    Artificial hip and knee maker Smith & Nephew (SN.L), a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere, where he oversaw its $5.3 billion sale to Abbott (ABT.N) in 2017. The medical technology firm, which also has wound-care and sports medicine units, is under pressure to improve margins and find new sources of growth as it competes with bigger rivals.

  • Reuters - UK Focus4 months ago

    Smith & Nephew picks new CEO who sold his last company

    Artificial hip and knee maker Smith & Nephew (Frankfurt: 502816 - news) , a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere (NYSE: ALR - news) , where he oversaw its $5.3 billion sale to Abbott in 2017.

  • Reuters - UK Focus4 months ago

    Smith & Nephew names Namal Nawana new CEO

    Artificial hip and knee maker Smith & Nephew said on Wednesday it had appointed Namal Nawana to replace Olivier Bohuon as chief executive of the British company next month. Nawana was most recently chief ...

  • Medical devices maker S&N to name Nawana as new chief
    Sky News4 months ago

    Medical devices maker S&N to name Nawana as new chief

    The FTSE-100 medical devices group Smith & Nephew (Frankfurt: 502816 - news) (S&N) will this week end its six-month search for a new boss by naming a former Alere (NYSE: ALR - news) executive to the role. Sky News has learnt that S&N will announce on Wednesday that Namal Nawana will join the global leader in orthopaedics reconstruction in the coming months. Mr Nawana, a 46-year-old Australian citizen, will replace Olivier Bohuon, who told the medical technology group's board last October that he intended to step down this year.

  • Smith & Nephew (SNN): Moving Average Crossover Alert
    Zacks4 months ago

    Smith & Nephew (SNN): Moving Average Crossover Alert

    Smith & Nephew plc (SNN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

  • Johnson & Johnson’s Acclarent Aera Balloon Dilation System
    Market Realist5 months ago

    Johnson & Johnson’s Acclarent Aera Balloon Dilation System

    Acclarent received FDA approval for its Acclarent Aera Balloon Dilation System for the treatment of ETD (eustachian tube dysfunction) in September 2016. For details, read Inside Johnson & Johnson’s Latest US Medical Device Launch. On February 27, 2018, Johnson & Johnson’s subsidiary Acclarent announced that the company received FDA approval for the expanded indication for Acclarent Aera.

  • Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
    Zacks5 months ago

    Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

    Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

  • How JNJ’s Orthopedic Medical Devices Performed in 4Q17 and 2017
    Market Realist5 months ago

    How JNJ’s Orthopedic Medical Devices Performed in 4Q17 and 2017

    How Johnson & Johnson's Medical Devices Business Fared in 2017

  • Business Wire5 months ago

    Smith & Nephew: RCT demonstrates a 71% reduction in the onset of sacral pressure ulcers when adding ALLEVYN◊ LIFE to standard preventative protocol

    LONDON--(BUSINESSWIRE)-- Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces the publication of a randomised controlled trial (RCT) demonstrating that the addition ...

  • Business Wire5 months ago

    Smith & Nephew: RCT demonstrates a 71% reduction in the onset of sacral pressure ulcers when adding ALLEVYN◊ LIFE to standard preventative protocol

    Smith & Nephew plc , the global medical technology business, today announces the publication of a randomised controlled trial demonstrating that the addition of ALLEVYN LIFE, Smith & Nephew’s leading multi-layer silicone adhesive foam dressing, to a standard care protocol significantly reduces the onset of pressure ulcers by 71% in elderly patients admitted to hospital for hip fracture1.

  • Reuters - UK Focus5 months ago

    Smith & Nephew meets lower end of guidance range for 2017

    Artificial hip and knee maker Smith & Nephew scraped into the bottom of its guidance range for 2017, with a 3 percent rise in revenue to $4.77 billion pounds and a 20 basis point increase in its trading ...

  • Reuters - UK Focus6 months ago

    Britain's FTSE dips as pound gain weighs on exporters

    The UK's top share index fell for a third straight day as a deepening global sell-off in the dollar strengthened sterling and dented earnings prospects for British companies exposed to the U.S. currency. ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes